logo

Hanmi Pharmaceutical

14, Wiryeseong-daero, Songpa-gu, Seoul, Korea


Update Date : 2024-12-23
Company information
Related News

  • Hanmi Pharmaceutical Co., Ltd., established in 1973, is a major South Korean pharmaceutical company based in Seoul. The company focuses on the development, manufacturing, and marketing of innovative drugs, with a strong emphasis on R&D. Hanmi's key products include Amosartan for hypertension and Esomezol for acid-related diseases. In 2023, Hanmi reported revenues of approximately $1.8 billion. The company allocates a significant portion of its revenue to R&D, fostering advancements in diabetes, obesity, and cancer treatments. Hanmi collaborates with international pharmaceutical companies to enhance its research capabilities and expand its global market presence, maintaining a commitment to improving public health.
  • Labscovery : platform technology that prolongs the active duration of biologics and makes it possible for once-weekly or monthly drug administration. PENTAMBODY : This platform allows the antibody to simultaneously bind two different targets for both immuno-oncology therapy and targeted therapy
  • Public
  • Pharma, Investor, CDMO, Bio
  • Code
    Phase III
    Efpeglenatide
    Obesity
    Code
    Phase III
    Poziotinib
    NSCLC
    Code
    Phase II
    Podeltinib
    B-cell lymphoma
    Code
    Phase II
    Tivumecirnon
    Stomach cancer
    Code
    Phase III
    Risuteganib
    Dry AMD
Copyright ⓒ BQURA, Mediandshare 2024

Publisher-Editor : Wan Ju (Jay) Kim

Address : 919, 33, International Finance Road 6-gil, Yeongdeungpo-gu, Seoul, Korea

Tel : 82-10-9336-6304 / [email protected]

Copyright ⓒ BQURA, Mediandshare 2024

BQURA